世界の原発性胆汁性胆管炎治療市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Primary Biliary Cholangitis Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12613 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、原発性胆汁性胆管炎治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。原発性胆汁性胆管炎治療の種類別市場規模（ウルソデオキシコール酸（UDCA）、オベチコール酸（Ocaliva））、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・原発性胆汁性胆管炎治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Novartis、Bristol-Myers Squibb、Pfizer、GlaxoSmithKline、Teva Pharmaceutical、Retrophin、Lumena Pharmaceuticals、Intercept Pharmaceuticals ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：ウルソデオキシコール酸（UDCA）、オベチコール酸（Ocaliva） ・用途別分析2016年-2026年：病院、クリニック、その他 ・原発性胆汁性胆管炎治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・原発性胆汁性胆管炎治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・原発性胆汁性胆管炎治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・原発性胆汁性胆管炎治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・原発性胆汁性胆管炎治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Primary Biliary Cholangitis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Primary Biliary Cholangitis Treatment size is estimated to be USD 1382.5 million in 2026 from USD 673.1 million in 2020, with a change XX% between 2020 and 2021. The global Primary Biliary Cholangitis Treatment market size is expected to grow at a CAGR of 19.7% for the next five years.

Market segmentation
Primary Biliary Cholangitis Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Ursodeoxycholic Acid (UDCA)
Obeticholic Acid (Ocaliva)

Market segment by Application, can be divided into
Hospitals
Clinics
Others

Market segment by players, this report covers
Novartis
Bristol-Myers Squibb
Pfizer
GlaxoSmithKline
Teva Pharmaceutical
Retrophin
Lumena Pharmaceuticals
Intercept Pharmaceuticals

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Primary Biliary Cholangitis Treatment
1.2 Classification of Primary Biliary Cholangitis Treatment by Type
1.2.1 Overview: Global Primary Biliary Cholangitis Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Primary Biliary Cholangitis Treatment Revenue Market Share by Type in 2020
1.2.3 Ursodeoxycholic Acid (UDCA)
1.2.4 Obeticholic Acid (Ocaliva)
1.3 Global Primary Biliary Cholangitis Treatment Market by Application
1.3.1 Overview: Global Primary Biliary Cholangitis Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Primary Biliary Cholangitis Treatment Market Size & Forecast
1.5 Global Primary Biliary Cholangitis Treatment Market Size and Forecast by Region
1.5.1 Global Primary Biliary Cholangitis Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Primary Biliary Cholangitis Treatment Market Size by Region, (2016-2021)
1.5.3 North America Primary Biliary Cholangitis Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Primary Biliary Cholangitis Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Primary Biliary Cholangitis Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Primary Biliary Cholangitis Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Primary Biliary Cholangitis Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Primary Biliary Cholangitis Treatment Market Drivers
1.6.2 Primary Biliary Cholangitis Treatment Market Restraints
1.6.3 Primary Biliary Cholangitis Treatment Trends Analysis
2 Company Profiles
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business
2.1.3 Novartis Primary Biliary Cholangitis Treatment Product and Solutions
2.1.4 Novartis Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Novartis Recent Developments and Future Plans
2.2 Bristol-Myers Squibb
2.2.1 Bristol-Myers Squibb Details
2.2.2 Bristol-Myers Squibb Major Business
2.2.3 Bristol-Myers Squibb Primary Biliary Cholangitis Treatment Product and Solutions
2.2.4 Bristol-Myers Squibb Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Primary Biliary Cholangitis Treatment Product and Solutions
2.3.4 Pfizer Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Pfizer Recent Developments and Future Plans
2.4 GlaxoSmithKline
2.4.1 GlaxoSmithKline Details
2.4.2 GlaxoSmithKline Major Business
2.4.3 GlaxoSmithKline Primary Biliary Cholangitis Treatment Product and Solutions
2.4.4 GlaxoSmithKline Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 GlaxoSmithKline Recent Developments and Future Plans
2.5 Teva Pharmaceutical
2.5.1 Teva Pharmaceutical Details
2.5.2 Teva Pharmaceutical Major Business
2.5.3 Teva Pharmaceutical Primary Biliary Cholangitis Treatment Product and Solutions
2.5.4 Teva Pharmaceutical Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Teva Pharmaceutical Recent Developments and Future Plans
2.6 Retrophin
2.6.1 Retrophin Details
2.6.2 Retrophin Major Business
2.6.3 Retrophin Primary Biliary Cholangitis Treatment Product and Solutions
2.6.4 Retrophin Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Retrophin Recent Developments and Future Plans
2.7 Lumena Pharmaceuticals
2.7.1 Lumena Pharmaceuticals Details
2.7.2 Lumena Pharmaceuticals Major Business
2.7.3 Lumena Pharmaceuticals Primary Biliary Cholangitis Treatment Product and Solutions
2.7.4 Lumena Pharmaceuticals Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Lumena Pharmaceuticals Recent Developments and Future Plans
2.8 Intercept Pharmaceuticals
2.8.1 Intercept Pharmaceuticals Details
2.8.2 Intercept Pharmaceuticals Major Business
2.8.3 Intercept Pharmaceuticals Primary Biliary Cholangitis Treatment Product and Solutions
2.8.4 Intercept Pharmaceuticals Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Intercept Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Primary Biliary Cholangitis Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Primary Biliary Cholangitis Treatment Players Market Share
3.2.2 Top 10 Primary Biliary Cholangitis Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Primary Biliary Cholangitis Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Primary Biliary Cholangitis Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Primary Biliary Cholangitis Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Primary Biliary Cholangitis Treatment Revenue Market Share by Application (2016-2021)
5.2 Primary Biliary Cholangitis Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Primary Biliary Cholangitis Treatment Revenue by Type (2016-2026)
6.2 North America Primary Biliary Cholangitis Treatment Revenue by Application (2016-2026)
6.3 North America Primary Biliary Cholangitis Treatment Market Size by Country
6.3.1 North America Primary Biliary Cholangitis Treatment Revenue by Country (2016-2026)
6.3.2 United States Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Primary Biliary Cholangitis Treatment Revenue by Type (2016-2026)
7.2 Europe Primary Biliary Cholangitis Treatment Revenue by Application (2016-2026)
7.3 Europe Primary Biliary Cholangitis Treatment Market Size by Country
7.3.1 Europe Primary Biliary Cholangitis Treatment Revenue by Country (2016-2026)
7.3.2 Germany Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
7.3.3 France Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Primary Biliary Cholangitis Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Primary Biliary Cholangitis Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Primary Biliary Cholangitis Treatment Market Size by Region
8.3.1 Asia-Pacific Primary Biliary Cholangitis Treatment Revenue by Region (2016-2026)
8.3.2 China Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
8.3.5 India Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Primary Biliary Cholangitis Treatment Revenue by Type (2016-2026)
9.2 South America Primary Biliary Cholangitis Treatment Revenue by Application (2016-2026)
9.3 South America Primary Biliary Cholangitis Treatment Market Size by Country
9.3.1 South America Primary Biliary Cholangitis Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Primary Biliary Cholangitis Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Primary Biliary Cholangitis Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Primary Biliary Cholangitis Treatment Market Size by Country
10.3.1 Middle East & Africa Primary Biliary Cholangitis Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Primary Biliary Cholangitis Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Primary Biliary Cholangitis Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Primary Biliary Cholangitis Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Primary Biliary Cholangitis Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Primary Biliary Cholangitis Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Primary Biliary Cholangitis Treatment Revenue Market Share by Region (2021-2026)
Table 6. Novartis Corporate Information, Head Office, and Major Competitors
Table 7. Novartis Major Business
Table 8. Novartis Primary Biliary Cholangitis Treatment Product and Solutions
Table 9. Novartis Primary Biliary Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 11. Bristol-Myers Squibb Major Business
Table 12. Bristol-Myers Squibb Primary Biliary Cholangitis Treatment Product and Solutions
Table 13. Bristol-Myers Squibb Primary Biliary Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Pfizer Corporate Information, Head Office, and Major Competitors
Table 15. Pfizer Major Business
Table 16. Pfizer Primary Biliary Cholangitis Treatment Product and Solutions
Table 17. Pfizer Primary Biliary Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 19. GlaxoSmithKline Major Business
Table 20. GlaxoSmithKline Primary Biliary Cholangitis Treatment Product and Solutions
Table 21. GlaxoSmithKline Primary Biliary Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Teva Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 23. Teva Pharmaceutical Major Business
Table 24. Teva Pharmaceutical Primary Biliary Cholangitis Treatment Product and Solutions
Table 25. Teva Pharmaceutical Primary Biliary Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Retrophin Corporate Information, Head Office, and Major Competitors
Table 27. Retrophin Major Business
Table 28. Retrophin Primary Biliary Cholangitis Treatment Product and Solutions
Table 29. Retrophin Primary Biliary Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Lumena Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 31. Lumena Pharmaceuticals Major Business
Table 32. Lumena Pharmaceuticals Primary Biliary Cholangitis Treatment Product and Solutions
Table 33. Lumena Pharmaceuticals Primary Biliary Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Intercept Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 35. Intercept Pharmaceuticals Major Business
Table 36. Intercept Pharmaceuticals Primary Biliary Cholangitis Treatment Product and Solutions
Table 37. Intercept Pharmaceuticals Primary Biliary Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Global Primary Biliary Cholangitis Treatment Revenue (USD Million) by Players (2019-2021)
Table 39. Global Primary Biliary Cholangitis Treatment Revenue Share by Players (2019-2021)
Table 40. Breakdown of Primary Biliary Cholangitis Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 41. Primary Biliary Cholangitis Treatment Players Head Office, Products and Services Provided
Table 42. Primary Biliary Cholangitis Treatment Mergers & Acquisitions in the Past Five Years
Table 43. Primary Biliary Cholangitis Treatment New Entrants and Expansion Plans
Table 44. Global Primary Biliary Cholangitis Treatment Revenue (USD Million) by Type (2016-2021)
Table 45. Global Primary Biliary Cholangitis Treatment Revenue Share by Type (2016-2021)
Table 46. Global Primary Biliary Cholangitis Treatment Revenue Forecast by Type (2021-2026)
Table 47. Global Primary Biliary Cholangitis Treatment Revenue by Application (2016-2021)
Table 48. Global Primary Biliary Cholangitis Treatment Revenue Forecast by Application (2021-2026)
Table 49. North America Primary Biliary Cholangitis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 50. North America Primary Biliary Cholangitis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 51. North America Primary Biliary Cholangitis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 52. North America Primary Biliary Cholangitis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 53. North America Primary Biliary Cholangitis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 54. North America Primary Biliary Cholangitis Treatment Revenue by Country (2021-2026) & (USD Million)
Table 55. Europe Primary Biliary Cholangitis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 56. Europe Primary Biliary Cholangitis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 57. Europe Primary Biliary Cholangitis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 58. Europe Primary Biliary Cholangitis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 59. Europe Primary Biliary Cholangitis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 60. Europe Primary Biliary Cholangitis Treatment Revenue by Country (2021-2026) & (USD Million)
Table 61. Asia-Pacific Primary Biliary Cholangitis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 62. Asia-Pacific Primary Biliary Cholangitis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 63. Asia-Pacific Primary Biliary Cholangitis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 64. Asia-Pacific Primary Biliary Cholangitis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 65. Asia-Pacific Primary Biliary Cholangitis Treatment Revenue by Region (2016-2021) & (USD Million)
Table 66. Asia-Pacific Primary Biliary Cholangitis Treatment Revenue by Region (2021-2026) & (USD Million)
Table 67. South America Primary Biliary Cholangitis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 68. South America Primary Biliary Cholangitis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 69. South America Primary Biliary Cholangitis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 70. South America Primary Biliary Cholangitis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 71. South America Primary Biliary Cholangitis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 72. South America Primary Biliary Cholangitis Treatment Revenue by Country (2021-2026) & (USD Million)
Table 73. Middle East & Africa Primary Biliary Cholangitis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 74. Middle East & Africa Primary Biliary Cholangitis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 75. Middle East & Africa Primary Biliary Cholangitis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 76. Middle East & Africa Primary Biliary Cholangitis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 77. Middle East & Africa Primary Biliary Cholangitis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 78. Middle East & Africa Primary Biliary Cholangitis Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Primary Biliary Cholangitis Treatment Picture
Figure 2. Global Primary Biliary Cholangitis Treatment Revenue Market Share by Type in 2020
Figure 3. Ursodeoxycholic Acid (UDCA)
Figure 4. Obeticholic Acid (Ocaliva)
Figure 5. Primary Biliary Cholangitis Treatment Revenue Market Share by Application in 2020
Figure 6. Hospitals Picture
Figure 7. Clinics Picture
Figure 8. Others Picture
Figure 9. Global Primary Biliary Cholangitis Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 10. Global Primary Biliary Cholangitis Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 11. Global Primary Biliary Cholangitis Treatment Revenue Market Share by Region (2016-2026)
Figure 12. Global Primary Biliary Cholangitis Treatment Revenue Market Share by Region in 2020
Figure 13. North America Primary Biliary Cholangitis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Europe Primary Biliary Cholangitis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Asia-Pacific Primary Biliary Cholangitis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. South America Primary Biliary Cholangitis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Middle East and Africa Primary Biliary Cholangitis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Primary Biliary Cholangitis Treatment Market Drivers
Figure 19. Primary Biliary Cholangitis Treatment Market Restraints
Figure 20. Primary Biliary Cholangitis Treatment Market Trends
Figure 21. Novartis Recent Developments and Future Plans
Figure 22. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 23. Pfizer Recent Developments and Future Plans
Figure 24. GlaxoSmithKline Recent Developments and Future Plans
Figure 25. Teva Pharmaceutical Recent Developments and Future Plans
Figure 26. Retrophin Recent Developments and Future Plans
Figure 27. Lumena Pharmaceuticals Recent Developments and Future Plans
Figure 28. Intercept Pharmaceuticals Recent Developments and Future Plans
Figure 29. Global Primary Biliary Cholangitis Treatment Revenue Share by Players in 2020
Figure 30. Primary Biliary Cholangitis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 31. Global Top 3 Players Primary Biliary Cholangitis Treatment Revenue Market Share in 2020
Figure 32. Global Top 10 Players Primary Biliary Cholangitis Treatment Revenue Market Share in 2020
Figure 33. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 34. Global Primary Biliary Cholangitis Treatment Revenue Share by Type in 2020
Figure 35. Global Primary Biliary Cholangitis Treatment Market Share Forecast by Type (2021-2026)
Figure 36. Global Primary Biliary Cholangitis Treatment Revenue Share by Application in 2020
Figure 37. Global Primary Biliary Cholangitis Treatment Market Share Forecast by Application (2021-2026)
Figure 38. North America Primary Biliary Cholangitis Treatment Sales Market Share by Type (2016-2026)
Figure 39. North America Primary Biliary Cholangitis Treatment Sales Market Share by Application (2016-2026)
Figure 40. North America Primary Biliary Cholangitis Treatment Revenue Market Share by Country (2016-2026)
Figure 41. United States Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Canada Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Mexico Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Europe Primary Biliary Cholangitis Treatment Sales Market Share by Type (2016-2026)
Figure 45. Europe Primary Biliary Cholangitis Treatment Sales Market Share by Application (2016-2026)
Figure 46. Europe Primary Biliary Cholangitis Treatment Revenue Market Share by Country (2016-2026)
Figure 47. Germany Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. France Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. United Kingdom Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Russia Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Italy Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Asia-Pacific Primary Biliary Cholangitis Treatment Sales Market Share by Type (2016-2026)
Figure 53. Asia-Pacific Primary Biliary Cholangitis Treatment Sales Market Share by Application (2016-2026)
Figure 54. Asia-Pacific Primary Biliary Cholangitis Treatment Revenue Market Share by Region (2016-2026)
Figure 55. China Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Japan Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. South Korea Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. India Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Southeast Asia Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Australia Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. South America Primary Biliary Cholangitis Treatment Sales Market Share by Type (2016-2026)
Figure 62. South America Primary Biliary Cholangitis Treatment Sales Market Share by Application (2016-2026)
Figure 63. South America Primary Biliary Cholangitis Treatment Revenue Market Share by Country (2016-2026)
Figure 64. Brazil Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Argentina Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Middle East and Africa Primary Biliary Cholangitis Treatment Sales Market Share by Type (2016-2026)
Figure 67. Middle East and Africa Primary Biliary Cholangitis Treatment Sales Market Share by Application (2016-2026)
Figure 68. Middle East and Africa Primary Biliary Cholangitis Treatment Revenue Market Share by Country (2016-2026)
Figure 69. Turkey Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Saudi Arabia Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. UAE Primary Biliary Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Methodology
Figure 73. Research Process and Data Source

---